Furthermore, NR4A2/hA1R engineered cells exhibited a similar frequency of TSCM CAR T cells in the spleen (Fig. 4H), indicating that linking A1R expression to CAR T cell activation at the tumor site overcame the deleterious effects on persistence. This evidence concerns the gene NR4A2 and neoplasm.